Resources from the same session
Introduction and scientific background
Presenter: Eva Ciruelos
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Slides
Webcast
ADCs for patients with triple negative breast cancer: Moving towards combinations with I-O and agents targeting DDR
Presenter: Aditya Bardia
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Slides
Webcast
Which impact of Her2-directed ADCs?
Presenter: Ian Krop
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Slides
Webcast
Finding the right population and combination to develop ADCs in patients with HR+/Her2- mBC
Presenter: Komal Jhaveri
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Eva Ciruelos
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
Resources:
Webcast